MindWalk Holdings (HYFT)
NASDAQ:HYFT
Want to see HYFT full AI Analyst Report?
HYFT Stock Chart & Stats
$1.32
--
Market closed
$1.32
--
Day’s Range― - ―
52-Week Range$0.40 - $3.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)381.97K
Market Cap
$59.79M
Enterprise Value$73.85M
Total Cash (Recent Filing)$14.18M
Total Debt (Recent Filing)$3.55M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Jul 23, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding46,711,864
10 Day Avg. Volume196,113
30 Day Avg. Volume381,969
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.85
Price to Sales (P/S)0.83
P/FCF Ratio-2.80
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue4.06
Enterprise Value/Gross Profit6.79
Enterprise Value/Ebitda-6.95
Forecast
1Y Price Target
$5.00Price Target Upside278.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$15.81M
Bulls Say, Bears Say
Bulls Say
Commercialization And Recurring RevenueSigning of an enterprise LensAI SaaS contract with a major client validates the HYFT architecture and shifts revenue toward predictable subscription streams, supporting scalable software-like margins as subscriptions grow.
Pipeline Partnership PotentialInternal programs targeting large markets, including a conserved-epitope dengue vaccine and obesity efforts, could drive out-licensing or strategic partnerships that materially increase valuation beyond current expectations.
Technology DifferentiationProprietary bio-native platform and LensAI knowledge graph connect biological sequence, structure, and function across multiomics and literature, increasing precision in early drug discovery and making the offering more attractive to pharmaceutical partners.
Bears Say
AI-driven Valuation PressureWidespread investor fears about artificial intelligence have pressured valuations across the software-driven drug discovery sector, which could continue to weigh on the stock despite improving fundamentals.
Investor Sentiment And Sell-off RiskPersistent skepticism in the SaaS and AI landscape may trigger additional sell-offs as investors remain cautious about commercializing AI tools, limiting near-term upside from emerging commercial traction.
MindWalk Holdings News
HYFT FAQ
What was MindWalk Holdings’s price range in the past 12 months?
MindWalk Holdings lowest stock price was $0.40 and its highest was $3.25 in the past 12 months.
What is MindWalk Holdings’s market cap?
MindWalk Holdings’s market cap is $59.79M.
When is MindWalk Holdings’s upcoming earnings report date?
MindWalk Holdings’s upcoming earnings report date is Jul 23, 2026 which is in 96 days.
How were MindWalk Holdings’s earnings last quarter?
MindWalk Holdings released its earnings results on Mar 12, 2026. The company reported -$0.058 earnings per share for the quarter, missing the consensus estimate of -$0.039 by -$0.019.
Is MindWalk Holdings overvalued?
According to Wall Street analysts MindWalk Holdings’s price is currently Undervalued.
Does MindWalk Holdings pay dividends?
MindWalk Holdings does not currently pay dividends.
What is MindWalk Holdings’s EPS estimate?
MindWalk Holdings’s EPS estimate is -0.05.
How many shares outstanding does MindWalk Holdings have?
MindWalk Holdings has 46,711,864 shares outstanding.
What happened to MindWalk Holdings’s price movement after its last earnings report?
MindWalk Holdings reported an EPS of -$0.058 in its last earnings report, missing expectations of -$0.039. Following the earnings report the stock price went up 2.344%.
Which hedge fund is a major shareholder of MindWalk Holdings?
Currently, no hedge funds are holding shares in HYFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (278.79% Upside)
$5.00 (278.79% Upside)
Blogger Sentiment
Bullish
HYFT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $150.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
209.13%
12-Months-Change
Fundamentals
Return on Equity
-63.13%
Trailing 12-Months
Asset Growth
-46.01%
Trailing 12-Months
Company Description
MindWalk Holdings
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
HYFT Company Deck
HYFT Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and scientific positives: robust revenue growth (Q3 +52% YoY, nine-month +45%), U.S. revenue doubling, the signing of the first enterprise recurring Lens AI platform contract, important preclinical pipeline discoveries (conserved dengue epitope, influenza conserved feature, GLP-1 activity vs semaglutide), peer-reviewed validation, and a new nanobody platform launch. Offsetting these strengths are higher operating expenses (notably S&M and R&D), a Q3 gross margin dip, ongoing net losses and cash burn ($10.1M YTD), and dependency on pending preclinical readouts and successful asset-level financing. Overall, the highlights—revenue acceleration, platform monetization, and differentiated scientific milestones—materially outweigh the lowlights tied to investment-driven losses and program-stage risk.View all HYFT earnings summariesHYFT Stock 12 Month Forecast
Average Price Target
$5.00
▲(278.79% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
7.97% Insiders
0.14% Mutual Funds
6.80% Other Institutional Investors
85.09% Public Companies and
Individual Investors